Stocks Under $10: First Bancorp

Richard Suttmeier  |

First Bancorp (FBP) – ($6.34) has a Buy rating according to ValuEngine with fair value at $25.36, which makes the stock 75.0% undervalued. The one-year price target is $6.73. ValuEngine Profile – “First Bancorp distinguished itself by providing innovative marketing strategies and novel products to attract clients. Besides the branches and lending offices, the Corporation has offered a telephone information service called Telebanco since 1983. This was the first telebanking service offered in Puerto Rico. The Corporation's clients have access to an extensive ATM network all over the world. The Corporation was the first in Puerto Rico to open on weekends and the first to offer in-store branches to its clients.”

Analysis – The daily chart for FBP shows rising momentum with the stock above its 21-day, 50-day and 200-day simple moving averages at $6.12, $6.05 and $5.05. My monthly value level is $6.21 with a quarterly risky level at $8.25.

 



Courtesy of Thomson / Reuters

 

Ticker

Company Name

Mkt Price

Fair Value

One-Year Price Target

Last 12-Mon Retn (%)

5-Yr Avg Retn (%)

P/E Ratio

FBP

FIRST BANCORP

6.34

25.36

6.73

93.88

-64.12

15.59

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
FBP First BanCorp. 11.15 0.00 0.00 2,805,582 Trade
OTEL Otelco Inc. 16.20 -0.33 -2.00 916 Trade

Comments


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 1

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 1 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.